openPR Logo
Press release

Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight

01-28-2025 07:52 PM CET | Health & Medicine

Press release from: ABNewswire

Hemophilia A FDA Approvals, Clinical Trials, Pipeline

DelveInsight's, "Hemophilia A Pipeline Insight" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hemophilia A Treatment Landscape. Click here to read more @ Hemophilia A Pipeline Outlook [https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hemophilia A Pipeline Report

* In January 2025:- CSL Behring:- A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A. For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight here

News-ID: 3837814 • Views:

More Releases from ABNewswire

School Lunch Angels Launches to Eliminate School Lunch Debt in Harris County
School Lunch Angels Launches to Eliminate School Lunch Debt in Harris County
Local 501(c)(3) nonprofit partners with community to ensure every child enjoys a nourishing, worry-free meal HAMILTON, GA - Oct 8th, 2025 - School Lunch Angels, Inc., Harris County's newest 501(c)(3) nonprofit organization, has officially launched with a mission to lift the burden of school lunch debt from families in Harris County and work hand-in-hand with schools to make school lunches something every child can look forward to. By ensuring that every
Sean McNamara'sBau, Artist at Warand Rising Music Star Ryn Kid Triumph at Infiniti MusicandFilm Awards
Sean McNamara'sBau, Artist at Warand Rising Music Star Ryn Kid Triumph at Infini …
The Infiniti Music and Film Awards [https://infinitimusicandfilmawards.net/] honored extraordinary achievements in cinema and music this year, with visionary filmmaker Sean McNamara's Bau, Artist at War and breakout artist Ryn Kid emerging as the evening's standout winners. Fresh from its nationwide release on September 26, 2025, Bau, Artist at War has already resonated deeply with audiences and critics alike, boasting an impressive 93% RT Popcorn Meter score and an A- CinemaScore. The
Cape Coral, FL Realtors Win Prestigious Quality Business Award, Joining Less Than 1% of American Businesses
Cape Coral, FL Realtors Win Prestigious Quality Business Award, Joining Less Tha …
Cape Coral, FL - Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agents in Cape Coral FL has earned the coveted Quality Business Award for 2025, a distinction reserved for businesses achieving an overall quality score of 95% or greater. This exclusive recognition represents the pinnacle of business excellence, awarded to fewer than 1% of all registered businesses across America. The award selection process begins with nominations from
CLM ENGLISH ACADEMY Launches Innovative Patent-Based English Camp in Phu Quoc, Vietnam
CLM ENGLISH ACADEMY Launches Innovative Patent-Based English Camp in Phu Quoc, V …
Image: https://www.abnewswire.com/upload/2025/10/b373b37e53188cf41a4a259ee3e45fb3.jpg CLM ENGLISH ACADEMY, a pioneering institution in English language education, proudly announces the launch of its unique English camp in the heart of Phu Quoc, Vietnam. With two educational Education patents and AI-related patent, CLM ENGLISH ACADEMY delivers an innovative, research-driven curriculum that combines cutting-edge technology with immersive learning experiences. Patented Curriculum for Effective Learning The academy's program provides students with a patent-backed, AI-enhanced English curriculum designed to make learning both

All 5 Releases


More Releases for Hemophilia

Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts What Is the Expected CAGR for the Hemophilia Market Through 2025? In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028. During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748 This latest report researches the industry structure,
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes